# Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

> **NCT06300489** · PHASE1 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** irinotecan liposomes+capecitabine

## Key facts

- **NCT ID:** NCT06300489
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-03
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06300489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06300489, "Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06300489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*